Balyasny Asset Management
ABMD

Balyasny Asset Management’s Abiomed Inc ABMD Stock Holding History

Balyasny Asset Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,000
Closed -$4.64M – 3343
2022
Q1 		$4.64M Buy
+14,000
New +$4.31M 0.01% 980
2021
Q3 		– Sell
-39,000
Closed -$12.2M – 2581
2021
Q2 		$12.2M Buy
+39,000
New +$12M 0.06% 446

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's ABMD Position: Q4 2022 in Review

Balyasny Asset Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 50,801 shares — an estimated $12.5M sold.

Balyasny Asset Management first reported a position in ABMD in Q4 2016 and held it in 11 quarters. The position peaked at $31.5M in Q4 2021. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Balyasny Asset Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 50,801 Abiomed Inc shares in Q4 2022, an estimated $12.5M.
  • Balyasny Asset Management first reported a position in Abiomed Inc in Q4 2016 and held it in 11 quarters.
  • Balyasny Asset Management's Abiomed Inc position peaked at $31.5M in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.